Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016
In this nationwide, population-based study, we assessed trends in primary treatment and survival among 687 patients with nodular lymphocyte-predominant Hodgkin lymphoma (75% males; median age, 40 years; and 74% stage-I/II disease) diagnosed in the Netherlands between 1993-2016. There were no noteworthy changes in the application of primary therapy over time among adult patients across the different disease stages and age groups. Survival among various subgroups of adult patients was largely comparable to the expected survival of the general population. A particularly encouraging finding was that young adult patients experienced virtually no excess mortality, as compared to the general population.
|Keywords||cancer epidemiology, incidence, nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), population-based registry, survival|
|Persistent URL||dx.doi.org/10.1111/bjh.16290, hdl.handle.net/1765/125985|
|Journal||British Journal of Haematology|
Posthuma, H.L.A, Zijlstra, J.M, Visser, O.J, Lugtenburg, P.J, Kersten, M.J, & Dinmohamed, A.G. (2020). Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016. British Journal of Haematology, 189(1), 117–121. doi:10.1111/bjh.16290